Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSalu, Bruno R. [UNIFESP]
dc.contributor.authorFerreira, Rodrigo S. [UNIFESP]
dc.contributor.authorBrito, Marlon V. [UNIFESP]
dc.contributor.authorOttaiano, Tatiana F. [UNIFESP]
dc.contributor.authorCruz, Jose Walber M. C. [UNIFESP]
dc.contributor.authorSilva, Mariana Cristina Cabral [UNIFESP]
dc.contributor.authorCorreia, Maria Tereza S.
dc.contributor.authorPaiva, Patricia M. G.
dc.contributor.authorMaffei, Francisco Humberto de Abreu
dc.contributor.authorOliva, Maria Luiza Vilela [UNIFESP]
dc.identifier.citationBiological Chemistry. Berlin: Walter de Gruyter Gmbh, v. 395, n. 9, p. 1027-1035, 2014.
dc.description.abstractArterial thrombosis is an important complication of diabetes and cancer, being an important target for therapeutic intervention. Crataeva tapia bark lectin (CrataBL) has been previously shown to have hypoglycemiant effect and also to induce cancer cell apoptosis. It also showed inhibitory activity against Factor Xa (K-iapp = 8.6 m). in the present study, we evaluated the anti-thrombotic properties of CrataBL in arterial thrombosis model. CrataBL prolongs the activated partial thromboplastin time on human and mouse plasma, and it impairs the heparin-induced potentiation of antithrombin III and heparin-induced platelet activation in the presence of low-dose ADP. It is likely that the dense track of positive charge on CrataBL surface competes with the heparin ability to bind to antithrombin III and to stimulate platelets. in the photochemically induced thrombosis model in mice, in the groups treated with 1.25, 5.0, or 10 mg/kg CrataBL, prior to the thrombus induction, the time of total artery occlusion was prolonged by 33.38%, 65%, and 66.11%, respectively, relative to the time of the control group. in contrast to heparin, the bleeding time in CrataBL-treated mice was no longer than in the control. in conclusion, CrataBL was effective in blocking coagulation and arterial thrombus formation, without increasing bleeding time.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.publisherWalter de Gruyter Gmbh
dc.relation.ispartofBiological Chemistry
dc.rightsAcesso restrito
dc.subjectantithrombin IIIen
dc.subjectblood coagulationen
dc.subjectKunitz inhibitoren
dc.titleCrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formationen
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHosp Santa Catarina
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade Federal de Pernambuco (UFPE)
dc.description.affiliationUNESP, Fac Med Botucatu, Dept Cirurgia & Ortopedia, BR-18618970 Botucatu, SP, Brazil
dc.description.affiliationHosp Santa Catarina, Ctr Estudos & Pesquisas, BR-01310000 São Paulo, SP, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Bioquim, BR-04044020 São Paulo, Brazil
dc.description.affiliationUniv Fed Pernambuco, Dept Bioquim, BR-50670901 Recife, PE, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Bioquim, BR-04044020 São Paulo, Brazil
dc.description.sponsorshipIDFAPESP: 2009/53766-5
dc.description.sourceWeb of Science
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.